Abstract
Purpose: Lung cancer is the leading cause of cancer death worldwide. The objective was to analyze survival for lung cancer in Granada, and to identify the factors influencing survival. Methods: Data were obtained from the population-based cancer registry in Granada (Spain). All cases of newly diagnosed primary lung cancer in 2011-2012 (n=685) were included. One and two-year relative survival was estimated. Results: Of our population, 65% of the patients were over 65 years of age, and 83% were men. 74% of patients had good performance status (PS); 81% of the tumors were microscopically verified; and 81% were non-small cell lung cancer. Overall, 16% were stage I-II, whereas 57% were stage IV. Radiotherapy was administered in 28% of cases, chemotherapy in 45%, whereas 23% of patients were operated. The two-year survival rate was 18% (67% and 5% for stage I and IV). Survival was higher among women (29%), <75 years of age (21.6%), and those with good PS (23%). Microscopic verification and surgery led to higher survival rates of 23.4% and 69%, respectively. Conclusions: Since the factors affecting survival were PS, stage, and surgery, efforts should target the early diagnosis of lung cancer since this would improve treatment options and outcomes.
Highlights
Isabel Linares1*, José Expósito2, Elena Molina-Portillo3,4, Yoe-Ling Chang3,4, Juan Pedro Arrebola2,3,4, Julia SánchezCantalejo3, Jaime Pérez-Alija5, Miguel Rodríguez-Barranco3,4, María Rosa Guerrero2 and María José Sánchez3,4
A total of 685 population-based lung cancer (LC) cases were included in the analysis
Morphology was unspecified in 2.3% of cases
Summary
Isabel Linares1*, José Expósito, Elena Molina-Portillo, Yoe-Ling Chang, Juan Pedro Arrebola, Julia SánchezCantalejo, Jaime Pérez-Alija, Miguel Rodríguez-Barranco, María Rosa Guerrero and María José Sánchez. Conclusions: Since the factors affecting survival were PS, stage, and surgery, efforts should target the early diagnosis of lung cancer since this would improve treatment options and outcomes. A population-based cancer survival analysis provides valuable information that can be used to assess healthcare performance in patients diagnosed with malignant tumors. This survival analysis is estimated from all incident cases within a cancer registry area over a certain time period and provides a valid measure of cancer care performance. [1] study, the European mean age-standardized 5-year survival for lung cancer (LC) was the poorest of the ten index cancers (13%, 95% CI 12.913.1) with a higher percentage for women than for men. The moderate progress achieved with these therapies has led to research on whether there are certain subgroups of LC patients that would benefit more from specific treatment strategies [2, 3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
